Loading...
Loading...
shares surged 86.14% to $1.88 in pre-market trading as Carl Icahn disclosed a 52.3% stake in the company.
Dyax Corp.DYAX shares gained 42.94% to $23.95 in the pre-market trading session after the company said a Phase Ib trial of its DX-2930 drug met safety goals and demonstrated statistically significant reductions in attack rates of hereditary angiodema, a rare disease.
Innocoll AG INNL shares climbed 10.25% to $8.28 in pre-market trading after the company reported that the results of a pharmacokinetic (PK) study support using a dose of 300 mg of XaraColl for phase 3 clinical studies in post-operative pain.
Sarepta Therapeutics, Inc. SRPT gained 7.30% to $14.25 in pre-market trading as the company named Edward Kaye as Interim CEO.
Esperion Therapeutics, Inc.ESPR shares rose 5.29% to $97.50 in pre-market trading. UBS initiated coverage on Esperion Therapeutics with a Buy rating and a $140.00 price target.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in